I have to hand it to you Respert—'The Sheath of Pharmaceuticlus' actually has a nice ring to it! If the board finds that easier to follow, I’m happy to adopt it.
But all jokes aside, you’ve actually hit on the three most important parts of the January 2026 Reality that everyone should understand:
Max (The 'Mentos-in-the-Cola'
: You’re right. Dr. Lataillade didn’t leave the top of ViiV/GSK for a 'nonsense' story. He brought that 'sleeve' of expertise because he knows exactly how to scale the PD-L1 wall.
The 'Chamber of Chili' (Boiling Point): Whether we call it 'Cold-to-Hot' or 'Boiling Point,' the clinical fact remains: Leronlimab is the Prime that unmasks the Tumor. Without that 'Boiling Point,' the ICIs (like Jemperli) are just expensive drugs with no target to hit.
The Sword (Expectations): My 'branding' is just a shorthand for the 700mg Sledgehammer. In my opinion, once the DSMB clears the path in March, the market's 'Expectations' of this being just another 'small cap' will be the only thing that breaks.
The Real Scoreboard: > While we laugh about the names, let’s not lose sight of the January 20, 2026, Pfizer exit. They took the money and cleared the deck. Now it's just GSK, Shionogi, and the clinical data.
I'll keep the 'branding' here to a minimum if it helps, but I won't stop pointing at the 88% Upregulation. That's the only 'truth serum' that matters to Merck and GSK.
But all jokes aside, you’ve actually hit on the three most important parts of the January 2026 Reality that everyone should understand:
Max (The 'Mentos-in-the-Cola'
: You’re right. Dr. Lataillade didn’t leave the top of ViiV/GSK for a 'nonsense' story. He brought that 'sleeve' of expertise because he knows exactly how to scale the PD-L1 wall. The 'Chamber of Chili' (Boiling Point): Whether we call it 'Cold-to-Hot' or 'Boiling Point,' the clinical fact remains: Leronlimab is the Prime that unmasks the Tumor. Without that 'Boiling Point,' the ICIs (like Jemperli) are just expensive drugs with no target to hit.
The Sword (Expectations): My 'branding' is just a shorthand for the 700mg Sledgehammer. In my opinion, once the DSMB clears the path in March, the market's 'Expectations' of this being just another 'small cap' will be the only thing that breaks.
The Real Scoreboard: > While we laugh about the names, let’s not lose sight of the January 20, 2026, Pfizer exit. They took the money and cleared the deck. Now it's just GSK, Shionogi, and the clinical data.
I'll keep the 'branding' here to a minimum if it helps, but I won't stop pointing at the 88% Upregulation. That's the only 'truth serum' that matters to Merck and GSK.
12
